On May 27, 2022 Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy’s") reported the launch of Pemetrexed for Injection, 100 mg and 500 mg Single-Dose Vials, the generic equivalent of ALIMTA (pemetrexed for injection) in the U.S. Market approved by the U.S. Food and Drug Administration (USFDA) (Press release, Dr Reddy’s, MAY 27, 2022, View Source [SID1234615210]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The ALIMTA brand and generic had U.S. sales of approximately $1239 million MAT for the most recent twelve months ending in March 2022 according to IQVIA Health*.

Dr. Reddy’s Pemetrexed for Injection is supplied in 100 mg and 500 mg single-dose vials.